Yanlin Yu,Mitchell Ho
Yanlin Yu
CAR-T cell therapy has shown promise but is constrained by side effects and limited efficacy in treating solid tumors. Compared to CAR-T cells, CAR natural killer (NK) cells derived from multiple versatile sources exhibit more favorable saf...
Structure and function of therapeutic antibodies approved by the US FDA in 2024 [0.03%]
2024年美国FDA批准的治疗性抗体的结构与功能
William R Strohl
William R Strohl
In 2024, the Food and Drug Administration approved 47 new molecular entities (NMEs), including 15 therapeutic antibody-based molecules, marking the 30th anniversary of the first approved recombinant antibody. Ten of these were recombinant i...
Reprogramming the tumor microenvironment: synergistic mechanisms of antibody-drug conjugates and immune checkpoint inhibitors [0.03%]
肿瘤微环境的重编程：抗体-药物偶联物与免疫检查点抑制剂协同作用机制
Ling Yin,Shoubing Zhou,Hongliang Zhang et al.
Ling Yin et al.
The integration of antibody-drug conjugates (ADCs) with immune checkpoint inhibitors (ICIs) represents a paradigm shift in oncology, combining targeted cytotoxicity and adaptive immune activation to overcome resistance in refractory tumors....
Broadly reactive anti-VHH antibodies for characterizing, blocking, or activating nanobody-based CAR-T cells [0.03%]
用于表征、阻断或激活纳米抗体基CAR-T细胞的广谱抗VHH抗体
Scott McComb,Bianca Dupont,Alex Shepherd et al.
Scott McComb et al.
Background: Production of chimeric antigen receptor T cell (CAR-T) therapies depends on antibody reagents to label, isolate, and expand T cell products. We sought to create antibody tools specific for the variable domain ...
Qingyan Hu,Yunsong Frank Li
Qingyan Hu
Drug product formulation transforms active pharmaceutical ingredients into drug products, ensuring stability, manufacturability, efficacy, and patient safety. Driven by biotech advancements and patient needs, new antibody-based therapies an...
Antibody-drug conjugates in cancer and beyond: progress, promise, and perspectives [0.03%]
抗体偶联药物在癌症等领域取得的进展、展望及前景
Victor S Goldmacher
Victor S Goldmacher
Antibody-drug conjugates (ADCs) are transforming cancer therapy by combining antibody specificity with potent cytotoxic agents, enabling targeted tumor cell killing while minimizing systemic toxicity. This special collection of Antibody The...
Correction to: Structure and function of therapeutic antibodies approved by the US FDA in 2024 [0.03%]
美国FDA于2024年批准的治疗性抗体的结构和功能的更正
[This corrects the article DOI: 10.1093/abt/tbaf014.]. © The Author(s) 2025. Published by Oxford University Press on behalf of the Chinese Antibody Soci...
Published Erratum
Antibody therapeutics. 2025 Aug 17;8(3):238. DOI:10.1093/abt/tbaf015 2025
Matching placebo development for injectable biologics-a practical tutorial [0.03%]
匹配安慰剂生物制品注射液的开发实践教程
Lun Xin,Zhe Zhang,Kushan Shah et al.
Lun Xin et al.
Background: In drug development, placebo-controlled trials are vital for assessing treatment efficacy. Developing a suitable placebo for injectable biologics presents unique challenges, particularly in matching the physic...
Bypassing the immunosuppressive effects of CA125/MUC16 via re-engineered rituximab (NAV-006) to improve its antitumor activity in vivo [0.03%]
通过改造的利妥昔单抗(NAV-006)绕过CA125/MUC16免疫抑制效应以提高其体内抗肿瘤活性
Luigi Grasso,Bradford J Kline,Nicholas C Nicolaides
Luigi Grasso
The monoclonal antibody rituximab functions through complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) and is used to treat non-Hodgkin's lymphoma. Elevated serum CA125/MUC16 levels, present in some ...
A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy [0.03%]
一种新型PD-L1/VEGF双特异性抗体CVL006用于癌症治疗优于AK112
Chunyan Wang,Hao Huang,Zeng Song et al.
Chunyan Wang et al.
Background: Preclinical and clinical studies highlight the enhanced anticancer efficacy of combining anti-VEGF/VEGFR drugs with immune checkpoint inhibitors (ICIs). PD-L1/VEGF bispecific antibodies outperform monotherapy ...